Pharmaceutical Research and Development: What Do We Get for All that Money?

BMJ, 2012, DOI: 10.1136/bmj.e4348

5 Pages Posted: 10 May 2013 Last revised: 19 Jun 2013

Donald W. Light

Rowan University School of Osteopathic Medicine ; Center for Migration and Development; Institute for Advanced Study

Joel Lexchin

York University

Date Written: August 7, 2012

Abstract

Data indicate that the widely touted “innovation crisis” in pharmaceuticals is a myth. The real innovation crisis, say Donald Light and Joel Lexchin, stems from current incentives that reward companies for developing large numbers of new drugs with few clinical advantages over existing ones.

Keywords: pharmaceuticals, pharmaceutical policy, regulation, innovation crisis

Suggested Citation

Light, Donald W. and Lexchin, Joel, Pharmaceutical Research and Development: What Do We Get for All that Money? (August 7, 2012). BMJ, 2012, DOI: 10.1136/bmj.e4348. Available at SSRN: https://ssrn.com/abstract=2262843 or http://dx.doi.org/10.2139/ssrn.2262843

Donald W. Light (Contact Author)

Rowan University School of Osteopathic Medicine ( email )

Cherry Hill, NJ 08003
United States
6092160071 (Phone)

Center for Migration and Development ( email )

200 Wallace Hall
Princeton, NJ 08544
United States
6092160071 (Phone)

Institute for Advanced Study ( email )

1 Einstein Drive
Princeton, NJ 08540
United States
(609) 734-8000 (Phone)

Joel Lexchin

York University ( email )

4700 Keele Street
Toronto, Ontario M3J 1P3
Canada
+416-736-2100 x 22119 (Phone)
+416-736-5227 (Fax)

Paper statistics

Downloads
712
Rank
27,320
Abstract Views
1,882